Parvus is pioneering a novel class of disease-modifying therapeutics – Navacims™ – that represent a paradigm shift in the way that autoimmune diseases are treated. Current approaches generally require broad suppression of the immune system to prevent immune attack against a patient’s own tissues. In contrast, our Navacim drug candidates are able to selectively blunt the action of pathogenic immune cells (including cytotoxic T cells and antigen-presenting cells), thereby restoring immune tolerance and potentially reversing disease.
Parvus has shown in multiple preclinical in-vivo models of autoimmune disease that its Navacims can reprogram disease- or tissue-specific cells to orchestrate reversal of disease, as published in leading peer-reviewed journals. Based on the Company’s broadly enabling therapeutic platform, Parvus has generated a robust R&D pipeline and is advancing several proprietary Navacim development candidates toward clinical testing.